Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance) in cases of impaired hepatic or renal function: A mechanism that may aid in the prevention of nephrogenic systemic fibrosis?

British Journal of Radiology

Volumn 88, Issue 1048, 2015, Pages

  Kirchin, M A ^a   Lorusso, V ^b   Pirovano, G ^c  

^a Bracco Imaging SpA   (Italy)

^b Ephoran Multi imaging Solutions srl   (Italy)

^c Bracco Research USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; GADOBENATE DIMEGLUMINE; ION; CONTRAST MEDIUM; GADOBENIC ACID; MEGLUMINE; ORGANOMETALLIC COMPOUND; GADOBENATE ION; GADOLINIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILIARY EXCRETION; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY FAILURE; LIVER FAILURE; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; RAT; URINARY EXCRETION; X RAY FLUORESCENCE; ANALOGS AND DERIVATIVES; ANIMAL; BILE; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; KIDNEY; LIVER; METABOLISM; RANDOMIZED CONTROLLED TRIAL; URINE; BLOOD ANALYSIS; BLOOD VESSEL OCCLUSION; BODY WEIGHT; DRUG DETERMINATION; DRUG ELIMINATION; DRUG MECHANISM; EXSANGUINATION; KIDNEY BLOOD VESSEL; KIDNEY CONCENTRATING CAPACITY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER DYSFUNCTION; LIVER FUNCTION; URINALYSIS;

ANIMALS; BILE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; IONS; KIDNEY; LIVER; MALE; MEGLUMINE; NEPHROGENIC FIBROSING DERMOPATHY; ORGANOMETALLIC COMPOUNDS; RATS; URINE;

EID: 84943399136     PISSN: 00071285     EISSN: 1748880X     Source Type: Journal    
DOI: 10.1259/bjr.20140526     Document Type: Article

References (69)

1. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001; 23: 383-93.
2. Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 2011; 65: 1095-106. doi: 10.1016/j. jaad.2010.08.041
3. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1.
4. Grobner T. Gadolinium-A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-8. Erratum in: Nephrol Dial Transplant 2006; 21: 1745.
5. Spinazzi A. MRI contrast agents and nephrogenic systemic fibrosis. In: Shellock FG, Crues JV, eds. MRI bioeffects, safety, and patient management. Los Angeles, CA: Biomedical Research Publishing Group; 2014. pp. 256-81.
6. Dawson P. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies. J Magn Reson Imaging 2008; 28: 797-804. doi: 10.1002/jmri.21521
7. van der Molen AJ. Nephrogenic systemic fibrosis and the role of gadolinium contrast media. J Med Imaging Radiat Oncol 2008; 52: 339-50. doi: 10.1111/j.1440-1673.2008.01965.x
8. Thomsen HS, Morcos SK, Almén T, Bellin MF, Bertolotto M, Bongartz G, et al; ESUR Contrast Medium Safety Committee. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2013; 23: 307-18. doi: 10.1007/s00330-012-2597-9
9. Gadolinium-containing contrast agents: new advice to minimise the risk of nephrogenic systemic fibrosis. [Updated 11 January 2010; accessed 12 February 2015.]. Available from: https://www.gov.uk/drug-safety-update/gadolinium-containing-contrast-Agents-newadvice-To-minimise-The-risk-of-nephrogenicsystemic-fibrosis
10. Hao D, Ai T, Goerner F, Hu X, Runge VM, Tweedle M. MRI contrast agents: basic chemistry and safety. J Magn Reson Imaging 2012; 36: 1060-71. doi: 10.1002/jmri.23725
11. Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 2009; 30: 1259-67. doi: 10.1002/jmri.21969
12. Parmelee DJ, Walovitch RC, Ouellet HS, Lauffer RB. Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. Invest Radiol 1997; 32: 741-7.
13. Hamm B, Staks T, Mühler A, Bollow M, Taupitz M, Frenzel T, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195: 785-92.
14. Schuhmann-Giampieri G, Mahler M, Röll G, Maibauer R, Schmitz S. Pharmacokinetics of the liver-specific contrast agent Gd-EOBDTPA in relation to contrast-enhanced liver imaging in humans. J Clin Pharmacol 1997; 37: 587-96.
15. Gschwend S, Ebert W, Schultze-Mosgau M, Breuer J. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol 2011; 46: 556-66. doi: 10.1097/RLI.0b013e31821a218a
16. MultiHance Summary of Product Characteristics (SPC). Bracco UK Ltd. High Wycombe, UK. [Accessed 12 February 2015.] Available from: https://www.medicines.org. uk/emc/medicine/6132
17. Ablavar [package insert]. North Billerica, MA: Lantheus Medical Imaging, Inc. [Accessed 12 February 2015.] Available from: http://www. accessdata.fda.gov/drugsatfda-docs/label/2010/021711s003lbl.pdf
18. Primovist Summary of Product Characteristics (SPC). Bayer plc. Newbury, UK. [Accessed 12 February 2015.] Available from: https://www.medicines.org.uk/emc/medicine/15927
19. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 1998; 33: 798-809.
20. Spinazzi A, Lorusso V, Pirovano GP, Kirchin M. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 1999; 6: 282-91.
21. Lorusso V, Arbughi T, Tirone P, de Häen C. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance). J Comput Assist Tomogr 1999; 23(Suppl. 1): S181-94.
22. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl. 1): S1-266.
23. Mühler A, Heinzelmann I, Weinmann HJ. Elimination of gadolinium-ethoxybenzyl-DTPA in a rat model of severely impaired liver and kidney excretory function. An experimental study in rats. Invest Radiol 1994; 29: 213-16.
24. Lorusso V, Poggesi I, Arbughi T, Dal Fiume D, Tirone P. High-performance liquid chromatographic assay of the magnetic resonance imaging contrast agent gadobenate in plasma, urine and bile. J Chromatogr B Biomed Appl 1994; 656: 415-22.
25. Arbughi T, Bartolomeo MP, Costa G, Lorusso V, Tirone P. X-ray fluorescence spectrometric determination of gadolinium in biological tissues. XXI National Congress of Analytical Chemistry. Book of abstracts Nr. SP21. Cagliari, Italy: Societa Chimica Italiana; 1994.
26. Baker HJ, Lindsey JR, Weisbroth SH, eds. Appendix 1. The laboratory, rat. volume 1. New York, NY: Academic Press; 1979. pp. 411-12.
27. de Häen C, Lorusso V, Tirone P. Hepatic transport of gadobenate dimeglumine in TRrats. Acad Radiol 1996; 3(Suppl. 2): S452-4.
28. Swan SK, Lambrecht LJ, Townsend R, Davies BE, McCloud S, Parker JR, et al. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 1999; 34: 443-8.
29. Davies BE, Kirchin MA, Bensel K, Lorusso V, Davies A, Parker JR, et al. Pharmacokinetics and safety of gadobenate dimeglumine (MultiHance) in subjects with impaired liver function. Invest Radiol 2002; 37: 299-308.
30. Jalandhara N, Arora R, Batuman V. Nephrogenic systemic fibrosis and gadoliniumcontaining radiological contrast agents: an update. Clin Pharmacol Ther 2011; 89: 920-3. doi: 10.1038/clpt.2010.346
31. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008; 43: 141-4. doi: 10.1097/RLI.0b013e31815a3407
32. Heverhagen JT, Krombach GA, Gizewski E. Application of extracellular gadoliniumbased MRI contrast agents and the risk of nephrogenic systemic fibrosis. Rofo 2014; 186: 661-9. doi: 10.1055/s-0033-1356403
33. Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006; 1: 128-37.
34. Idée JM, Port M, Robic C, Medina C, Sabatou M, Corot C. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging 2009; 30: 1249-58. doi: 10.1002/jmri.21967
35. Wollanka H, Weidenmaier W, Giersig C. NSF after Gadovist exposure: a case report and hypothesis of NSF development. Nephrol Dial Transpl 2009; 24: 3882-4. doi: 10.1093/ndt/gfp494
36. Elmholdt TR, Jrgensen B, Ramsing M, Pedersen M, Olesen AB. Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. Nephrol Dial Transpl Plus 2010; 3: 285-7.
37. Collidge T, Thomson P, Mark P, Willinek W, Roditi G. Is this really a true case of NSF following Gadovist exposure alone? Nephrol Dial Transpl 2010; 25: 1352-3; author reply 1353-4. doi: 10.1093/ndt/gfq014
38. Morcos SK, Dawson P. Comments on the case report reported by Elmholdt et al. Nephrol Dial Transpl Plus 2010; 3: 501-2; author reply 502-3.
39. Forsting M, Palkowitsch P. Prevalence of acute adverse reactions to gadobutrol-A highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials. Eur J Radiol 2010; 74: e186-92. doi: 10.1016/j.ejrad.2009.06.005
40. Pintaske J, Martirosian P, Graf H, Erb G, Lodemann KP, Claussen CD, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006; 41: 213-21. Erratum in: Invest Radiol 2006; 41: 859.
41. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40: 715-24.
42. Cavagna FM, Maggioni F, Castelli PM, Dapra M, Imperatori LG, Lorusso V, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997; 32: 780-96.
43. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, Siegler P, von der Lieth CW, Frank M, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. Invest Radiol 2006; 41: 222-8.
44. Kanal E, Maravilla K, Rowley HA. Gadolinium contrast agents for CNS imaging: current concepts and clinical evidence. AJNR Am J Neuroradiol 2014; 35: 2215-26. doi: 10.3174/ajnr.A3917
45. Maravilla KR, Maldjian JA, Schmalfuss IM, Kuhn MJ, Bowen BC, Wippold FJ 2nd, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 2006; 240: 389-400.
46. Rowley HA, Scialfa G, Gao PY, Maldjian JA, Hassell D, Kuhn MJ, et al. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol 2008; 29: 1684-91. doi: 10.3174/ajnr.A1185
47. Seidl Z, Vymazal J, Mechl M, Goyal M, Herman M, Colosimo C, et al. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol 2012; 33: 1050-8. doi: 10.3174/ajnr.A3033
48. Pediconi F, Catalano C, Occhiato R, Venditti F, Fraioli F, Napoli A, et al. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine. Radiology 2005; 237: 45-56.
49. Pediconi F, Catalano C, Padula S, Roselli A, Dominelli V, Cagioli S, et al. Contrastenhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine. AJR Am J Roentgenol 2008; 191: 1339-46. doi: 10.2214/AJR.07.3533
50. Martincich L, Faivre-Pierret M, Zechmann CM, Corcione S, van den Bosch HC, Peng WJ, et al. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for breast MR imaging (DETECT Trial). Radiology 2011; 258: 396-408. doi: 10.1148/radiol.10100968
51. Gerretsen SC, le Maire TF, Miller S, Thurnher SA, Herborn CU, Michaely HJ, et al. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries. Radiology 2010; 255: 988-1000. doi: 10.1148/radiol.10090357
52. Pediconi F, Fraioli F, Catalano C, Napoli A, Danti M, Francone M, et al. Gadobenate dimeglumine (Gd-DPTA) vs gadopentetate dimeglumine (Gd-BOPTA) for contrastenhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio. [In English, Italian.] Radiol Med 2003; 106: 87-93.
53. Prokop M, Schneider G, Vanzulli A, Goyen M, Ruehm SG, Douek P, et al. Contrastenhanced MR angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 2005; 234: 399-408.
54. Li Y, Li X, Li D, Lu J, Xing X, Yan F, et al. Multicenter, intraindividual comparison of single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine for MR angiography of the supra-Aortic arteries (the Supra-Aortic Value Study). AJNR Am J Neuroradiol 2013; 34: 847-54. doi: 10.3174/ajnr.A3298
55. Wang J, Yan F, Liu J, Lu J, Li D, Luan J, et al. Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the peripheral VALUE study). J Magn Reson Imaging 2013; 38: 926-37. doi: 10.1002/jmri.24040
56. Woodard PK, Chenevert TL, Sostman HD, Jablonski KA, Stein PD, Goodman LR, et al. Signal quality of single dose gadobenate dimeglumine pulmonary MRA examinations exceeds quality of MRA performed with double dose gadopentetate dimeglumine. Int J Cardiovasc Imaging 2012; 28: 295-301. doi: 10.1007/s10554-011-9821-6
57. Thurnher SA, Capelastegui A, Del Olmo FH, Dondelinger RF, Gervás C, Jassoy AG, et al. Safety and effectiveness of single-versus triple-dose gadodiamide injection-enhanced MR angiography of the abdomen: a phase III double-blind multicenter study. Radiology 2001; 219: 137-46.
58. Krause U, Kroencke T, Spielhaupter E, Taupitz M, Kenn W, Hamm B, et al. Contrast-enhanced magnetic resonance angiography of the lower extremities: standard-dose vs. high-dose gadodiamide injection. J Magn Reson Imaging 2005; 21: 449-54.
59. Schaefer PJ, Boudghene FP, Brambs HJ, Bret-Zurita M, Caniego JL, Coulden RA, et al. Abdominal and iliac arterial stenoses: comparative double-blinded randomized study of diagnostic accuracy of 3D MR angiography with gadodiamide or gadopentetate dimeglumine. Radiology 2006; 238: 827-40.
60. Schneider G, Ballarati C, Grazioli L, Manfredi R, Thurnher S, Kroencke TJ, et al. Gadobenate dimeglumine-enhanced MR angiography: diagnostic performance of four doses for detection and grading of carotid, renal, and aorto-iliac stenoses compared to digital subtraction angiography. J Magn Reson Imaging 2007; 26: 1020-32.
61. OHare A, Johansen K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol 2001; 12: 2838-47.
62. Matsumae T, Abe Y, Murakami G, Ishihara M, Ueda K, Saito T. Determinants of arterial wall stiffness and peripheral artery occlusive disease in nondiabetic hemodialysis patients. Hypertens Res 2007; 30: 377-85.
63. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamideassociated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007; 188: 586-92.
64. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148-57.
65. Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, et al. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 2008; 51: 966-75. doi: 10.1053/j. ajkd.2007.12.036
66. Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, et al. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology 2009; 253: 81-9. doi: 10.1148/radiol.2531082160
67. de Campos RO, Heredia V, Ramalho M, De Toni MS, Lugo-Somolinos A, Fuller ER 3rd, et al. Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations. AJR Am J Roentgenol 2011; 196: 545-52. doi: 10.2214/AJR.10.4500
68. ACR Manual on Contrast Media. V. 9. 2013. [Accessed 12 February 2015.] Available from http://www.acr.org/quality-safety/resources/;/media/37D84428BF1D4E1B9A3A2918-DA9E27A3.pdf
69. Guideline on the use of gadoliniumcontaining MRI contrast agents in patients with renal impairment v. 2. 2013. The Royal Australian and New Zealand College of Radiologists. [Accessed 12 February 2015.] Available from: http://www.ranzcr.edu.au/documents-download/doc-download/553-revised-college-guidelines-for-gadoliniumcontaining-mri-contrast-Agents.pdf